Table 7.
Examination characteristics in MDZ group and DEX group after propensity score matching.
| MDZ group | DEX group | p-value | |
|---|---|---|---|
| N | 91 | 91 | |
| Insertion route | |||
| Peroral | 45 (49.5%) | 45 (49.5%) | 1.000 |
| Transanal | 46 (50.5%) | 46 (50.5%) | |
| Scopes | |||
| Therapeutic (EN-450T, 580T) | 70 (76.9%) | 71 (78.0%) | 0.859 |
| Diagnostic (EN-450P, 580XP) | 21 (23.1%) | 20 (22.0%) | |
| Polypectomy | 4 (4.4%) | 8 (8.8%) | 0.232 |
| Hemostasis | 5 (5.5%) | 2 (2.2%) | 0.444 |
| Endoscopic balloon dilation | 7 (7.7%) | 3 (3.3%) | 0.193 |
| Endoscopic ultrasound | 3 (3.3%) | 7 (7.7%) | 0.193 |
| Duration of insertion (min) | 45.7 ± 24.8 | 44.1 ± 19.0 | 0.871 |
| Total duration of examination (min) | 66.5 ± 24.1 | 67.6 ± 25.9 | 0.678 |
| MDZ (mg) | 17.7 ± 5.8 | 3.4 ± 2.5 | <0.001 |
| Pentazocine (mg) | 17.3 ± 7.0 | 25.7 ± 15.7 | <0.001 |
MDZ: midazolam; DEX: dexmedetomidine.